CAMBRIDGE, Mass., Feb. 11, 2021 /PRNewswire/ — Iterative Scopes, a leading Artificial Intelligence in Gastroenterology provider, today unveiled a partnership with Eli Lilly and Company. Despite significant advancements in our understanding of inflammatory bowel disease (IBD) pathophysiology and target identification, progress in IBD research is hampered by variability in the human interpretation of endoscopic severity. Both companies recognize the need to integrate novel methods of interpreting and integrating visual data into the assessment of clinical trial endoscopic endpoints, reducing clinical trial costs, and speeding the assessment of clinical trial data. The initial focus of this collaboration is to work together to advance machine learning algorithms being developed by Iterative Scopes to improve upon current endoscopic clinical trial endpoint assessments, with the goal of advancing the use of AI applications for IBD clinical trials.
Keep Reading
Add A Comment